Tarlatamab
As of the edition of 20 October 2026, Tarlatamab is an antibody: marketed, first approved in 2024 (US); acts on CD3D, CD3E and CD3G and 1 more; US protection ends in 2036.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Antibody
- Brand name
- Imdelltra
- First approved
- 16 May 2024 (US)
- Approvals on record
- 8 in 5 regions
- Holder of the most recent approval
- Amgen; 2 holders in all
- Registered trials
- 39, 2 stopped early
- Disease areas
- Cancer; Lungs and airways; Chemically induced; Injuries; Nervous system; Urinary and reproductive
US protection
US protection ends in 2036.
US protection ends in 2036, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Amgen. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Tarlatamab.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 10 | 2 | 8 | 0 |
| Phase 2 | 21 | 0 | 19 | 2 |
| Phase 3 | 7 | 0 | 7 | 0 |
| All trials | 39 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Amgen | Originator, Applicant and Lead sponsor of trials | 2024 to now |